- Home
- TC vs TENX Comparison
TC vs TENX Comparison
Compare TC & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TC
- TENX
- Stock Information
- Founded
- TC 2010
- TENX 1967
- Country
- TC China
- TENX United States
- Employees
- TC 116
- TENX N/A
- Industry
- TC Business Services
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- TC Consumer Discretionary
- TENX Health Care
- Exchange
- TC Nasdaq
- TENX Nasdaq
- Market Cap
- TC 25.0M
- TENX 27.3M
- IPO Year
- TC 2018
- TENX N/A
- Fundamental
- Price
- TC $14.83
- TENX $6.44
- Analyst Decision
- TC
- TENX Strong Buy
- Analyst Count
- TC 0
- TENX 4
- Target Price
- TC N/A
- TENX $16.67
- AVG Volume (30 Days)
- TC 29.8K
- TENX 47.8K
- Earning Date
- TC 08-29-2025
- TENX 11-12-2025
- Dividend Yield
- TC N/A
- TENX N/A
- EPS Growth
- TC N/A
- TENX N/A
- EPS
- TC N/A
- TENX N/A
- Revenue
- TC $5,115,721.00
- TENX N/A
- Revenue This Year
- TC N/A
- TENX N/A
- Revenue Next Year
- TC N/A
- TENX N/A
- P/E Ratio
- TC N/A
- TENX N/A
- Revenue Growth
- TC N/A
- TENX N/A
- 52 Week Low
- TC $9.20
- TENX $3.25
- 52 Week High
- TC $86.00
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- TC 54.66
- TENX 72.57
- Support Level
- TC $13.00
- TENX $6.02
- Resistance Level
- TC $15.50
- TENX $6.50
- Average True Range (ATR)
- TC 2.19
- TENX 0.17
- MACD
- TC 0.26
- TENX 0.04
- Stochastic Oscillator
- TC 30.22
- TENX 93.16
About TC TuanChe Limited
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.